Expression of 12 cytokines in aqueous humour of uveal melanoma before and after combined Ruthenium-106 brachytherapy and transpupillary thermotherapy

Acta Ophthalmologica

Volumn 90, Issue 4, 2012, Pages

  Lee, Christopher Seungkyu ^a   Jun, Ik Hyun ^a   Kim, Tae Im ^a   Byeon, Suk Ho ^a   Koh, Hyoung Jun ^a   Lee, Sung Chul ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

angiogenesis; brachytherapy; cytokine; inflammation; uveal melanoma

Indexed keywords

CYTOKINE; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; RUTHENIUM 106; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AQUEOUS HUMOR; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYTOKINE RESPONSE; DOWN REGULATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; RADIATION DOSE; RETINA DETACHMENT; THERAPY EFFECT; TRANSPUPILLARY THERMOTHERAPY; TUMOR MICROENVIRONMENT; TUMOR VOLUME; UPREGULATION; UVEA MELANOMA;

ADULT; AGED; AQUEOUS HUMOR; BRACHYTHERAPY; COMBINED MODALITY THERAPY; CYTOKINES; EYE PROTEINS; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; MALE; MELANOMA; MIDDLE AGED; PROTEIN ARRAY ANALYSIS; RUTHENIUM RADIOISOTOPES; UVEAL NEOPLASMS;

EID: 84862787694     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2012.02392.x     Document Type: Article

References (38)

1. Atkins MB, Lotze MT, Dutcher JP, et al., (1999): High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17: 2105-2116.
2. Bar-Eli M, (1999): Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology 67: 12-18.
3. Bartlema YM, Oosterhuis JA, Journee-De Korver JG, Tjho-Heslinga RE, &, Keunen JE, (2003): Combined plaque radiotherapy and transpupillary thermotherapy in choroidal melanoma: 5 years' experience. Br J Ophthalmol 87: 1370-1373.
4. Canataroglu H, Varinli I, Ozcan AA, Canataroglu A, Doran F, &, Varinli S, (2005): Interleukin (IL)-6, interleukin (IL)-8 levels and cellular composition of the vitreous humor in proliferative diabetic retinopathy, proliferative vitreoretinopathy, and traumatic proliferative vitreoretinopathy. Ocul Immunol Inflamm 13: 375-381.
5. Char DH, Kroll S, Phillips TL, &, Quivey JM, (2002): Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy. Ophthalmology 109: 1850-1854.
6. Collaborative Ocular Melanoma Study Group. (2006): The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 124: 1684-1693.
7. Colombo MP, Maccalli C, Mattei S, Melani C, Radrizzani M, &, Parmiani G, (1992): Expression of cytokine genes, including IL-6, in human malignant melanoma cell lines. Melanoma Res 2: 181-189.
8. Cools-Lartigue J, Marshall JC, Caissie AL, Saraiva VS, &, Burnier MN Jr, (2004): Secretion of interleukin-6 and prostaglandin E2 during uveal melanoma-monocyte in vitro interactions. Exp Eye Res 79: 451-454.
9. Damato B, Patel I, Campbell IR, Mayles HM, &, Errington RD, (2005): Local tumor control after 106Ru brachytherapy of choroidal melanoma. Int J Radiat Oncol Biol Phys 63: 385-391.
10. Damato B, Duke C, Coupland SE, Hiscott P, Smith PA, Campbell I, Douglas A, &, Howard P, (2007): Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology 114: 1925-1931.
11. Elgert KD, Alleva DG, &, Mullins DW, (1998): Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 64: 275-290.
12. Fujimoto H, Sangai T, Ishii G, Ikehara A, Nagashima T, Miyazaki M, &, Ochiai A, (2009): Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int J Cancer 125: 1276-1284.
13. Hallermalm K, Seki K, De Geer A, et al., (2008): Modulation of the tumor cell phenotype by IFN-gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes. J Immunol 180: 3766-3774.
14. Hanahan D, &, Weinberg RA, (2000): The hallmarks of cancer. Cell 100: 57-70.
15. Ijland SA, Jager MJ, Heijdra BM, Westphal JR, &, Peek R, (1999): Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines. Melanoma Res 9: 445-450.
16. Katerinaki E, Evans GS, Lorigan PC, &, MacNeil S, (2003): TNF-alpha increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes. Br J Cancer 89: 1123-1129.
17. Kawano M, Hirano T, Matsuda T, et al., (1988): Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83-85.
18. Koga M, Kai H, Egami K, et al., (2008): Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice. Biochem Biophys Res Commun 365: 279-284.
19. Kujala E, Makitie T, &, Kivela T, (2003): Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 44: 4651-4659.
20. Kvanta A, Steen B, &, Seregard S, (1996): Expression of vascular endothelial growth factor (VEGF) in retinoblastoma but not in posterior uveal melanoma. Exp Eye Res 63: 511-518.
21. Lee CS, Lee J, Choi JJ, Yang WI, Yoon JS, Lee SY, &, Lee SC, (2011): Cytogenetics and prognosis for uveal melanoma in Korean patients. Acta Ophthalmol 89: e310-e314.
22. Lejeune FJ, Ruegg C, &, Lienard D, (1998): Clinical applications of TNF-alpha in cancer. Curr Opin Immunol 10: 573-580.
23. Li A, Dubey S, Varney ML, Dave BJ, &, Singh RK, (2003): IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 170: 3369-3376.
24. Likhvantseva VG, Slepova OS, &, Brovkina AF, (1999): [Interferon status of patients with uveal melanoma]. Vestn oftalmol 115: 35-37.
25. Ly LV, Bronkhorst IH, van Beelen E, Vrolijk J, Taylor AW, Versluis M, Luyten GP, &, Jager MJ, (2010): Inflammatory cytokines in eyes with uveal melanoma and relation with macrophage infiltration. Invest Ophthalmol Vis Sci 51: 5445-5451.
26. Makitie T, Summanen P, Tarkkanen A, &, Kivela T, (2001): Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci 42: 1414-1421.
27. Martin D, Galisteo R, &, Gutkind JS, (2009): CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem 284: 6038-6042.
28. Meeren AV, Bertho JM, Vandamme M, &, Gaugler MH, (1997): Ionizing radiation enhances IL-6 and IL-8 production by human endothelial cells. Mediators Inflamm 6: 185-193.
29. Missotten GS, Notting IC, Schlingemann RO, Zijlmans HJ, Lau C, Eilers PH, Keunen JE, &, Jager MJ, (2006): Vascular endothelial growth factor a in eyes with uveal melanoma. Arch Ophthalmol 124: 1428-1434.
30. Molloy RM, Mc Connell RI, Lamont JV, &, FitzGerald SP, (2005): Automation of biochip array technology for quality results. Clin Chem Lab Med 43: 1303-1313.
31. Oosterhuis JA, Journee-de Korver HG, Kakebeeke-Kemme HM, &, Bleeker JC, (1995): Transpupillary thermotherapy in choroidal melanomas. Arch Ophthalmol 113: 315-321.
32. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, &, Becher R, (1996): Prognostic implications of monosomy 3 in uveal melanoma. Lancet 347: 1222-1225.
33. Puusaari I, Heikkonen J, &, Kivela T, (2004): Ocular complications after iodine brachytherapy for large uveal melanomas. Ophthalmology 111: 1768-1777.
34. Sheidow TG, Hooper PL, Crukley C, Young J, &, Heathcote JG, (2000): Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis. Br J Ophthalmol 84: 750-756.
35. Shields CL, Cater J, Shields JA, Chao A, Krema H, Materin M, &, Brady LW, (2002): Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: tumor control and treatment complications in 270 consecutive patients. Arch Ophthalmol 120: 933-940.
36. Toivonen P, &, Kivela T, (2010): Infiltrating macrophages in extratumoural tissues after brachytherapy of uveal melanoma. Acta Ophthalmol. [Epub ahead of print].
37. Whitcup SM, Stark-Vancs V, Wittes RE, Solomon D, Podgor MJ, Nussenblatt RB, &, Chan CC, (1997): Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma. Arch Ophthalmol 115: 1157-1160.
38. Yang W, Chen PW, Li H, Alizadeh H, &, Niederkorn JY, (2008): PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro. Invest Ophthalmol Vis Sci 49: 2518-2525.